Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02917720
Other study ID # ELN-002
Secondary ID 2015-004998-33
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date September 2016
Est. completion date September 2027

Study information

Verified date December 2023
Source European LeukemiaNet
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main goal of the study is the assessment of duration of major molecular response (MMR) or better at 12 and 36 months after stopping tyrosine kinase inhibitors (TKI) therapy a second or third time in patients with at least three years prior TKI treatment comprising at least two years of nilotinib treatment within this trial and maintained stable MR4 (BCR-ABL ratio <0,01% on international Scale (IS) for at least one year and MR4.5 (BCR-ABL ratio <0,0032% on IS) for at least 6 months: - who failed a first stop in the EURO-SKI study (standardized criteria) - who failed a first or second stop outside the EURO-SKI study but would have had fulfilled same eligible criteria and were stopped according to EURO-SKI rules - who failed a first or second stop outside the EURO-SKI study without fulfilling EURO-SKI rules


Description:

The proposal is to re-treat patients with a minimum of two years with nilotinib 2x300 mg/d resulting in total of at least three years TKI treatment who show recurrent disease after unsuccessful first or second stop after TKI treatment in or outside the EURO-SKI study. If MR4 or better is re-achieved and maintained for at least one year and MR4.5 or better is re-achieved and maintained for at least 6 months, patients will be eligible for a second stop attempt within this study. For MR4, three consecutive PCRs with MR4 or deeper should be measured within one year and for MR4.5, two PCRs during 6 months should demonstrate a MR4.5. Patients who exhibited hematological relapse after the first stop attempt will not be eligible for a second stop attempt within this study. After inclusion, 3 monthly monitoring will be performed under nilotinib treatment within the trial. Patients fulfilling the criteria mentioned above will then enter the screening phase. After verification of MR4.5, TKI treatment will be stopped and patients followed in the same manner as described in EURO-SKI (monthly PCRs for 6 months, 6-weekly PCRs 7-12 months after stopping, thereafter 3-monthly). If MMR is lost (BCR-ABL >0.1% (IS)), TKI treatment will once again be restarted; here the same TKI (nilotinib) is recommended. It is assumed that after failure of first (or second) stop a switch to treatment with 2GTKI may increase the chance of stopping a second (or third) time [Legros et al. Blood 2012; Rea et al. Blood 2014] It is expected that the rate of a successful second (or third) stop at 12 and 36 months is more than 25%.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 75
Est. completion date September 2027
Est. primary completion date September 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age = 18 years - Patients with Ph chromosome and/or the BCR-ABL (either b3a2 and /or b2a2) fusion gene positive CML - CML in CP having failed a prior attempt to stop imatinib or other TKIs therapy either within EURO-SKI or not - Pretreatment at least one year with any TKI after 1st stop - Written informed consent Exclusion Criteria: - Previous hematological relapse after first stop of TKI. - Failure to any TKI at any time during CML treatment according to current ELN criteria - Previous planned or performed allo SCT - Previous AP/BC at any time in the history of the disease - High cardiac risk according to ESC score (= 10 Points) - Impaired cardiac function including any of the following: - Use of a ventricular paced pacemaker; congenital long QT syndrome or family history of; history or presence of significant ventricular or atrial tachyarrhythmias; clinically significant resting bradycardia (<50 bpm); QTcF >450 msec at baseline, myocardial infarction before baseline; other clinically significant heart disease (e.g., unstable angina, congestive heart failure, or uncontrolled hypertension). - Treatment with inhibitors of CYP3A4 or medications that have been well documented to prolong the QT interval is contraindicated. - History of acute pancreatitis within one year of study entry or medical history of chronic pancreatitis. - Positive hepatitis B virus serology test or HBV infection - Any other malignancy except if neither clinically significant nor requires active intervention. - Severe or uncontrolled medical conditions (i.e., uncontrolled diabetes, acute or chronic liver disease, pancreatic, or severe renal disease unrelated to tumor, active or uncontrolled infection). - Women who are pregnant, breast feeding, or of childbearing potential without a negative serum pregnancy test at baseline. Male or female patients of childbearing potential unwilling to use an effective barrier contraceptive method

Study Design


Related Conditions & MeSH terms


Intervention

Other:
TKI discontinuation
2nd or 3rd TKI stop after pre-treatment with nilotinib.
Drug:
nilotinib
Pre-treatment with nilotinib 300 mg/bid for 2 years

Locations

Country Name City State
Germany Universitätsklinikum der RWTH Aachen
Germany Klinikum Bayreuth Bayreuth
Germany Klinikum Chemnitz Chemnitz
Germany Onkologische Schwerpunktpraxis Esslingen
Germany Universitätsklinikum Freiburg Freiburg Baden-Württemberg
Germany Universitätsklinikum Halle (Saale) Halle (Saale)
Germany Medizinische Hochschule Hannover Hannover NRW
Germany Schwerpunktpraxis Onkologie Heilbronn
Germany Universitätsmedizin Mannheim Mannheim Baden-Württemberg
Germany Klinikum der Philipps-Universität Marburg
Germany Klinikum rechts der Isar München Bayern
Germany Kliniken Ostalb, Stauferklinikum Schwäbisch Gmünd Mutlangen
Germany Universitätsklinikum Rostock Rostock
Germany Schwarzwald-Baar Klinikum Villingen-Schwenningen
Netherlands Amsterdam UMC, locatie VUmc Amsterdam

Sponsors (3)

Lead Sponsor Collaborator
European LeukemiaNet Heidelberg University, Ludwig-Maximilians - University of Munich

Countries where clinical trial is conducted

Germany,  Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assessment of duration of MMR or better at 12 months after stopping TKI therapy a second or third time Assessment of duration of MMR or better at 12 months after stopping TKI therapy a second time in patients with at least three years prior TKI treatment comprising at least two years of nilotinib treatment within this trial and maintained stable MR4 for at least one year and MR4.5 for at least 6 months 12 months after stopping
Secondary Assessment of quality of life (QoL) profiles under nilotinib treatment and comparison with previous TKI therapy before switch and after stopping To investigate QoL changes over time in relapse-free patients without TKI re-start as measured by the EORTC QLQ-C30 and CML 24 (one combined questionnaire) 5 years
Secondary Identification of clinical and biological factors correlating with the persistence of MMR or better after stopping TKI Proportion of high risk patients according to the risk score at 6 months after stopping TKI; 6 months after stopping
Secondary Estimation of overall survival Overall survival is calculated from the date of 2nd stop of TKI treatment until the date of death irrespective of the cause of death. Patients still alive at the date of analysis will be censored at the date of last follow-up. 3 years
Secondary Time to re-achievement of MR4.5 after restart of therapy Assessment of molecular response after 3 years 3 years
Secondary Number of patients with grade 1 through grade 5 adverse events (AEs) that are related to study drug, graded according to NCI CTCAE Version 3.0 Assessment of incidence of any AEs (e.g. from musculoskeletal system) that arise after stopping TKI treatment a second time 3 years
Secondary Assessment of duration of MMR or better Assessment of duration of MMR or better at 36 months after stopping TKI therapy a second or third time in patients with at least three years prior TKI treatment comprising at least two years of nilotinib treatment 36 months after stopping
Secondary Number of patients with grade 1 through grade 5 adverse events (AEs) that are related to study drug, graded according to NCI CTCAE Version 3.0 Assessment of incidence of any AEs (e.g. from musculoskeletal system) that arise after stopping TKI treatment a second time 2 years treatment with nilotinib 300 mg/bid
Secondary Estimation of progression-free survival Progression-free survival is defined as overall survival plus the additional events progression to accelerated phase or blast crisis that also terminate PFS 3 years
Secondary Identification of clinical and biological factors correlating with the persistence of MMR or better after 6 months Proportion of female patients without molecular relapse 6 months after stopping
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Completed NCT02057185 - Occupational Status and Hematological Disease
Recruiting NCT03326310 - Selumetinib and Azacitidine in High Risk Chronic Blood Cancers Phase 1
Recruiting NCT04621851 - Retro-prospective Observational Study on Risk of Progression in CP-CML Patients Eligible for TKI Discontinuation
Completed NCT01207440 - Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL) Phase 2
Not yet recruiting NCT06409936 - PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML Phase 2
Not yet recruiting NCT02883036 - Vitro Study of Tigecycline to Treat Chronic Myeloid Leukemia N/A
Withdrawn NCT01188889 - RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease. Phase 1/Phase 2
Completed NCT01795716 - Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body Phase 1
Completed NCT00988013 - Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies N/A
Approved for marketing NCT00905593 - Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Phase 3
Terminated NCT00573378 - Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia Phase 2
Completed NCT00469014 - Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia Phase 2
Terminated NCT00522990 - Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias Phase 1/Phase 2
Completed NCT00257647 - Use of SV40 Vectors to Treat Chronic Myeloid Leukemia (CML) N/A
Unknown status NCT00598624 - Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) Phase 2
Completed NCT00219739 - STI571 ProspectIve RandomIzed Trial: SPIRIT Phase 3
Completed NCT06148493 - Real-World Usage of Asciminib Among Patients With Chronic Myeloid Leukemia in Chronic Phase in the United States Using a Large Claims Database
Completed NCT00375219 - Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation Phase 2
Completed NCT04605211 - A Distress Reduction Intervention for Patients With BCR-ABL-Negative MPNs or CML on Tyrosine Kinase Inhibitors N/A